Spots Global Cancer Trial Database for A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
Official Title: A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
Study ID: NCT03425565
Interventions
Study Description
Brief Summary: PEACOCC is a multi-centre, single arm, single stage phase II trial. The overall aim is to determine whether treatment with pembrolizumab is effective in patients with advanced clear cell gynaecological cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Western General Hospital, Edinburgh, , United Kingdom
University College Hospital, London, , United Kingdom
The Christie Hospital, Manchester, , United Kingdom
Mount Vernon Hospital, Northwood, , United Kingdom
Churchill Hospital, Oxford, , United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
